Background: Identification of protein biomarkers associated with incident atrial fibrillation (AF) may improve the understanding of the pathophysiology, risk prediction, and development of new therapeutics for AF. We examined the associations between 85 protein biomarkers and incident AF.
Methods: We included participants ≥50 years of age from the FHS (Framingham Heart Study) Offspring and Third Generation cohorts, who had 85 fasting plasma proteins measured using Luminex xMAP platform. Hazard ratios (per 1 SD increment of rank-normalized biomarker [hazard ratio]) and 95% CIs for incident AF were calculated using Cox regression models adjusted for age, sex, height, weight, current smoking, systolic blood pressure, diastolic blood pressure, hypertension treatment, diabetes mellitus, valvular heart disease, prevalent myocardial infarction, and prevalent heart failure. We used the false discovery rate to account for multiple testing.
Results: The study sample comprised 3378 participants (54% women) with mean (SD) age of 61.5 (8.4) years. In total, 401 developed AF over a mean follow-up of 12.3±3.8 years. We observed lower hazard of incident AF associated with higher mean levels of IGF1 (insulin-like growth factor 1; hazard ratio per 1 SD increment in protein level, 0.84 [95% CI, 0.76-0.93]), and higher hazard of incident AF associated with higher mean levels of both IGFBP1 (insulin-like growth factor-binding protein 1; hazard ratio, 1.24 [95% CI, 1.1-1.39]) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; hazard ratio, 1.73 [95% CI, 1.52-1.96]).
Conclusions: Decreased levels of IGF1 and increased levels of IGFBP1 and NT-proBNP were associated with higher risk of incident AF.
Keywords: atrial fibrillation; biomarkers; brain natriuretic peptide; hypertension; risk assessment.
Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study.Europace. 2017 Mar 1;19(3):364-370. doi: 10.1093/europace/euw017. Europace. 2017. PMID: 27194537
N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.Circulation. 2009 Nov 3;120(18):1768-74. doi: 10.1161/CIRCULATIONAHA.109.873265. Epub 2009 Oct 19. Circulation. 2009. PMID: 19841297 Free PMC article.
Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.Am Heart J. 2018 Oct;204:119-127. doi: 10.1016/j.ahj.2018.07.008. Epub 2018 Aug 10. Am Heart J. 2018. PMID: 30099337 Free PMC article.
Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study.J Am Heart Assoc. 2019 Aug 6;8(15):e012200. doi: 10.1161/JAHA.119.012200. Epub 2019 Aug 5. J Am Heart Assoc. 2019. PMID: 31379242 Free PMC article.
Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis.Scand J Clin Lab Invest. 2016 Oct;76(6):460-4. doi: 10.1080/00365513.2016.1199048. Epub 2016 Jun 27. Scand J Clin Lab Invest. 2016. PMID: 27347749 Review.
- R01 HL139731/HL/NHLBI NIH HHS/United States
- K24 HL105780/HL/NHLBI NIH HHS/United States
- HHSN268201500001C/HL/NHLBI NIH HHS/United States
- R01 HL092577/HL/NHLBI NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States